BioMetals

, Volume 23, Issue 2, pp 185–196

HIV therapeutic possibilities of gold compounds

  • Pascaline N. Fonteh
  • Frankline K. Keter
  • Debra Meyer
Article

Abstract

Highly active antiretroviral therapy (HAART) has resulted in decreased mortality and morbidity from the acquired immune deficiency syndrome caused by the human immunodeficiency virus (HIV). Drug resistance and toxicity of HAART has led to the search for novel inhibitors of HIV infection. Gold-based compounds have shown promising activity against a wide range of clinical conditions and microorganism infections including HIV-1. A typical example is auranofin which resulted in an elevated CD4+ T-cell count in an HIV patient being treated for psoriatic arthritis. In addition, reports exist on gold-based inhibitors of reverse transcriptase (RT), protease (PR) and viral entry of host cells. These and other characteristics of gold-based HIV drugs are reviewed here.

Keywords

Gold Inhibitors HIV AIDS 

Abbreviations

(H2TMPyP)4+

Meso-tetrakis(N-methlypyridinium-4-yl)porphyrin

AIDS

Acquired immune deficiency syndrome

Au(CN)2

Dicyanogold

AuTG

Aurothioglucose

AuTM

Aurothiomalate

[bpzmH2][AuCl4][Cl]

Tetra-chloro-(bis-(3,5-dimethlypyrazolyl)methane)gold(III) chloride

CCR5

Chemokine receptor 5

CD25

Cluster of differentiation 25

CD4

Cluster of differentiation 4

CD45

Cluster of differentiation 45

CD8

Cluster of differentiation 8

CEM, MT-4, OM10.1, Ach2

Cell line abbreviations

Cys

Cyteine

DNA

Deoxyribonucleic acid

GST

Gold sodium thiomalate

H2dcbpb

4,5-Dichloro-1,2-bis(2-(4-tert-butylpyridine)carboxamido)benzene

H2salen

N,N′-ethylenebis(salicylideneimine

HAART

Highly active antiretroviral therapy

HAuCl3

Hydrogen gold chloride

HIV

Human immunodeficiency virus

IL

Interleukin

IL-2R

Interleukin-2 receptor

NF-κB

Nuclear factor kappa B

NP

Nanoparticle

PBMCs

Peripheral blood mononuclear cells

PR

Protease

RNA

Ribonucleic acid

RT

Reverse transcriptase

TG

Thioglucose

TNF-α

Tumor necrosis factor-alpha

TPP

meso-Tetraarylporphyrin

References

  1. Ahmad S (2004) The chemistry of cyano complexes of gold (I) with emphasis on ligand scrambling reactions. Coord Chem Rev 248:231–243CrossRefGoogle Scholar
  2. Allaudeen HS, Snyder RM, Whitman MH, Crooke ST (1985) Effects of coordinated gold compounds on in vitro and in situ DNA replication. Biochem Pharmacol 34:3243–3250CrossRefPubMedGoogle Scholar
  3. Angela C, Christian H, Chiara G, Enrico M, Paul JD, Bernard KK, Luigi M (2008) Gold(III) compounds as anticancer agents: Relevance of gold–protein interactions for their mechanism of action. J Inorg Biochem 102:564–575 and references thereinCrossRefGoogle Scholar
  4. Argyris EG, Vanderkooi JM, Venkateswaran PS, Kay BK, Paterson Y (1999) The connection domain is implicated in metalloporphyrin binding and inhibition of HIV reverse transcriptase. J Biol Chem 274:1549–1556CrossRefPubMedGoogle Scholar
  5. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishim M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96:5698–5703CrossRefPubMedGoogle Scholar
  6. Best SL, Sadler PJ (1996) Gold drugs: mechanism of action and toxicity. Gold Bulletin 29:87–93Google Scholar
  7. Blough H, Ricchetti M, Montagnier L, Buc H (1989) Organic gold compounds are effective against HIV-1 reverse transcriptase, vol 5. International conference on AIDS, Jun 4–9, p 559Google Scholar
  8. Bowman M, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C (2008) Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc 130:6896–6897CrossRefPubMedGoogle Scholar
  9. Caruthers SD, Wickline SA, Lanza GM (2007) Nanotechnological applications in medicine. Curr Opin Biotechnol 18:26–30CrossRefPubMedGoogle Scholar
  10. Che C-M (2004) Methods for using gold (III) complexes as anti-tumor and anti-HIV agents United States, patent: 2004, Pub No WO/2004/024146Google Scholar
  11. Che C-M, Sun RW-Y, Yu W-Y, Ko C-B, Zhu N, Sun H (2003) Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. Chem Commun (14):1718–1719Google Scholar
  12. Crilly A, Madhok R, Watson J, Capell HA, Sturrock RD (1994) Production of interleukin 6 by monocytes isolated from rheumatoid arthritis patients receiving second line drug therapy. Br J Rheumatol 33:821–825CrossRefPubMedGoogle Scholar
  13. Espinoza LR, Aguilar JL, Berman A, Gutierrez F, Vasey FB, Germain BF (1989) Rheumatic manifestations associated with human immunodeficiency virus infection. Arthritis Rhuem 32:1615–1622CrossRefGoogle Scholar
  14. Fonteh P, Meyer D (2009) Novel gold(I) phosphine compounds inhibit HIV-1 enzymes Metallomics 1:427–433Google Scholar
  15. Fonteh PN, Keter FK, Guzei I, Darkwa J, Meyer D (2009) Tetra-chloro-(bis-3, 5-dimethylpyraxol)methane)gold(III)chloride: an HIV-1 reverse transcriptase and protease inhibitor. J Inorg Biochem 103:190–194CrossRefPubMedGoogle Scholar
  16. Fricker SP (1996a) Medical uses of gold compounds: past, present and future. Gold Bulletin 29(2):53–59Google Scholar
  17. Fricker SP (1996b) Medicinal chemistry and pharmacology of gold compounds. Trans Metal Chem 21:377–383CrossRefGoogle Scholar
  18. Gibbs EJ, Maurer MC, Zhang JH, Reiff WM, Hill DT, Malicka-Blaszkiewicz M, McKinnie ER, Liu H-Q, Pasternack RF (1988) Interactions of porphyrins with DNA and more highly organised structures. J Inorg Biochem 32:39–65CrossRefPubMedGoogle Scholar
  19. Huaizhi Z, Yuantao N (2001) China’s ancient gold drugs. Gold Bulletin 34(1):24–29Google Scholar
  20. Keter FK, Ojwach SO, Oyetunji OA, Guzei IA, Darkwa J (2008) Bis(pyrazolyl)palladium(II), platinum(II) and gold(III) complexes: synthesis, molecular structures and reaction kinetics with l-Cysteine. Inorg Chim Acta 362:2595–2602Google Scholar
  21. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Falloon J, Polis MA, Walker RE, Stevens R, Salzman NP, Metcalf JA, Masur H, Lane HC (1995) Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Eng J Med 335:1350–1356CrossRefGoogle Scholar
  22. Leibfarth JH, Persellin RH (1981) Mechanism of action of gold. Agents and Actions 11:458–472CrossRefPubMedGoogle Scholar
  23. Liu H-Q, Cheung T-C, Peng S-M, Che, C-M (1995) Novel luminescent cyclometalated and terpyridine gold(III) complexes and DNA binding studies. J Chem Soc Chem Commun 1787–1788Google Scholar
  24. Loetscher P, Dewald B, Baggiolini M, Seitz M (1994) Monocyte chemottractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs. Cytokine 6:162–170CrossRefPubMedGoogle Scholar
  25. Madhok R, Crilly A, Murphy E, Smith J, Watson J, Capell HA (1993) Gold therapy lowers serum interleukin levels in rheumatoid arthritis. J Rheumatol 20:630–633PubMedGoogle Scholar
  26. Mascarenhas B, Granda J, Freyberg R (1972) Gold metabolism in patients with rheumatoid arthritis treated with gold compounds-reinvestigated. J Rheumatol 23:1818–1820Google Scholar
  27. Miller S (2002) Beyond the CD4 count. The clinician’s guide to the immunity of HIV infection. Beckman Coulter 3(7):19–23, 27Google Scholar
  28. Navarro M (2009) Gold complexes as potential anti-parasitic agents. Coord Chem Rev 253:1619–1625CrossRefGoogle Scholar
  29. Navarro M, Perez H, Sanchez-Delgado GA, Schmidbaur H (1997) Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and Antimalarial Activity in vitro and in vivo of the New Gold-Chloroquine Complex (Au(PPh3)(CQ))PF6. J Med Chem 40:1937–1939CrossRefPubMedGoogle Scholar
  30. Okada T, Patterson BK, Ye S, Gurney ME (1993) Aurothiolates inhibit HIV-1 infectivity by gold (I) ligand exchange with a component of the virion surface. Virology 192:631–642CrossRefPubMedGoogle Scholar
  31. Pallela FJ, Delaney KM, Moorman AC, Loveless MM, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advance human Immunodeficiency virus infection. HIV outpatient study investigations. N Engl J Med 338:853–860CrossRefGoogle Scholar
  32. Parish RV, Cottrill SM (1987) Medicinal gold compounds. Gold bulletin 20(1/2):3–11Google Scholar
  33. Sadler PJ, Guo Z (1998) Metal complexes in medicine: design and mechanism of action. Pure Appl Chem 70(4):863–871CrossRefGoogle Scholar
  34. Sadler PJ, Li H, Sun H (1999) Coordination chemistry of metals in medicine: target sites for bismuth. Coord Chem Rev 185–186:689–709CrossRefGoogle Scholar
  35. Safarian D, Carnec X, Tsamis F, Kajumo F, Dragic T (2006) An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology 352:477–484CrossRefPubMedGoogle Scholar
  36. Saqqioro D, Rigobello MP, Paloschi L, Folda A, Moqqach SA, Parsons S, Ronconi L, Fregona D, Bindoli A (2007) Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem Biol 14:1128–1139 (references therein)Google Scholar
  37. Seitz M, Dewald B, Ceska M, Gerber N, Baggiolini M (1992) Interleukin-8 in inflammatory rheumatic diseases : synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol Int 12:159–164CrossRefPubMedGoogle Scholar
  38. Shapiro DL, Masci JR (1996) Treatment of HIV associated psoriatic arthritis with oral gold. J Rheumatol 23:1818–1820PubMedGoogle Scholar
  39. Shaw CF III (1979) The mammalian biochemistry of gold: an inorganic perspective of chrysotherapy. Inorg Perspect Biol Med 2:287–355Google Scholar
  40. Shaw CF III (1999) Gold-based therapeutic agents. Chem Rev 99:2589–2600CrossRefGoogle Scholar
  41. Stern I, Wataha JC, Lewis JB, Messer RLW, Lockwood PE, Tseng WY (2005) Anti-rheumatic gold compounds as sublethal modulators of monocytic LPS-induced cytokine secretion. Toxicol In Vitro 19:365–371CrossRefPubMedGoogle Scholar
  42. Suerbaum S, Michetti PN (2002) Helicobacter pylori infection. N Engl J Med 347:1175–1186CrossRefPubMedGoogle Scholar
  43. Sun RW-Y, Sun H, Che C-M (2004) In vitro inhibition of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase by gold(III) porphyrins. Chem Bio Chem 5:1293–1298PubMedGoogle Scholar
  44. Sun RW-Y, Ma D-L, Wong EL-M, Che C-M (2007) Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans 43:4884–4892PubMedGoogle Scholar
  45. Sutton BM (1986) Gold compounds for rheumatoid arthritis. Gold Bulletin 19(1):15–16Google Scholar
  46. Tepperman K, Zhang Y, Roy PW, Floyd R, Zhao Z, Dorsey JG, Elder RC (1994) Transport of the diacyanogold (I) anion. Met Based Drugs 1(5–6):433–443CrossRefPubMedGoogle Scholar
  47. Traber KE, Okamoto H, Kurono C, Baba M, Saliou C, Soji T, Parker L, Okamoto T (1999) Anti-rheumatoid compound aurothioglucose inhibits tumour necrosis-α-induced HIV-1 replication in latently infected OM10.1 and Ach2 cells. Int Immunol 1(2):143–150CrossRefGoogle Scholar
  48. Wanchu A (2003) HIV infection: rheumatic manifestation. J Indian Rheumatol Assoc 11:121–130Google Scholar
  49. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Xiaoyun WX, Salaza-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM (2003) Antibody neutralization and escaby by HIV-1. Nature 422:307–312CrossRefPubMedGoogle Scholar
  50. Yamaguchi K, Ushijima H, Hisano M, Inoue Y, Shimamura T, Hirano T, Muller WEG (2001) Immunodeficiency effect of gold sodium thiomalate on murine acquired immunodeficiency syndrome. Microbiol Immunol 45:549–555PubMedGoogle Scholar
  51. Yang JP, Merin JP, Nakano T, Kato T, Kitade S, Okamoto T (1995) Inhibition of the DNA-binding activity of NF-kappa B by gold compounds in vitro. FEBS Letters 361:89–96CrossRefPubMedGoogle Scholar
  52. Yanni G, Nabil M, Farahat MR, Poston RN, Panayi GS (1994) Intramuscular gold decreases cytokine expression and macrophage numbers in the rehumatoid synovial membrane. Ann Rheum Dis 53:315–322Google Scholar
  53. Yoshida S, Kato T, Sakurada S, Kurono C, Yang JP, Matsui N, Soji T, Okamoto T (1998) Inhibition of IL-6 and IL-8 induction from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose. Int Immunol 11:151–158CrossRefGoogle Scholar
  54. Zhang Y, Hess EV, Pryhuber KG, Dorsey JG, Tepperman K, Elder RC (1995) Gold binding sites in red blood cells. Inorg Chim Acta 229:271–280CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Pascaline N. Fonteh
    • 1
  • Frankline K. Keter
    • 1
  • Debra Meyer
    • 1
  1. 1.Department of BiochemistryUniversity of PretoriaPretoriaSouth Africa

Personalised recommendations